Moderna and Mitsubishi Tanabe Pharma have entered a collaboration to jointly promote the former’s mRNA respiratory vaccine portfolio in Japan.
The deal includes the promotion of Moderna’s Covid-19 vaccine, Spikevax.
The companies aim to maximise public health impact by ensuring broad access to these vaccines.
The initial term of the agreement extends until 31 March 2029.
Moderna and Mitsubishi Tanabe did not disclose further financial details of the deal.
Moderna will be responsible for the manufacture, sales, medical education and supply of its mRNA respiratory vaccines in the country.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Moderna Japan president and representative director Kazumasa Nagayama stated: “We are pleased to partner with Mitsubishi Tanabe Pharma to enable the commercialisation of our Covid-19 vaccine and future mRNA respiratory vaccine portfolio to the people of Japan.
“Mitsubishi Tanabe Pharma has a significant heritage in Japan, has long contributed to public health through numerous vaccines and possesses extensive experience and deep knowledge in this area. We look forward to working together to provide our Covid-19 vaccine in Japan, given the virus continues to pose a significant threat to public health.”
Mitsubishi Tanabe, part of Mitsubishi Chemical, is focused on central nervous system disorders, immuno-inflammation, diabetes and kidney diseases, and cancer.
Mitsubishi Tanabe Pharma representative director Akihiro Tsujimura said: “Moderna has delivered Covid-19 vaccines to many people worldwide since the Covid-19 pandemic began.
“We are delighted to collaborate with Moderna and engage in commercial activities for the Covid-19 vaccine and other mRNA respiratory vaccines in Japan. We will continue to contribute to public health in Japan through our vaccine business.”
mRNA vaccine coverage on Pharmaceutical Technology (Or Clinical Trials Arena) is supported by Trilink. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
